{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:42:58Z","timestamp":1789350178065,"version":"build-2803163510"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            EDP-239, a novel hepatitis C virus (HCV) inhibitor targeting nonstructural protein 5A (NS5A), has been investigated\n            <jats:italic>in vitro<\/jats:italic>\n            and\n            <jats:italic>in vivo<\/jats:italic>\n            . EDP-239 is a potent, selective inhibitor with potency at picomolar to nanomolar concentrations against HCV genotypes 1 through 6. In the presence of human serum, the potency of EDP-239 was reduced by less than 4-fold. EDP-239 is additive to synergistic with other direct-acting antivirals (DAAs) or host-targeted antivirals (HTAs) in blocking HCV replication and suppresses the selection of resistance\n            <jats:italic>in vitro<\/jats:italic>\n            . Furthermore, EDP-239 retains potency against known DAA- or HTA-resistant variants, with half-maximal effective concentrations (EC\n            <jats:sub>50<\/jats:sub>\n            s) equivalent to those for the wild type. In a phase I, single-ascending-dose, placebo-controlled clinical trial, EDP-239 demonstrated excellent pharmacokinetic properties that supported once daily dosing. A single 100-mg dose of EDP-239 resulted in reductions in HCV genotype 1a viral RNA of &gt;3 log\n            <jats:sub>10<\/jats:sub>\n            IU\/ml within the first 48 h after dosing and reductions in genotype 1b viral RNA of &gt;4-log\n            <jats:sub>10<\/jats:sub>\n            IU\/ml within 96 h. (This study has been registered at ClinicalTrials.gov under identifier NCT01856426.)\n          <\/jats:p>","DOI":"10.1128\/aac.00808-16","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T02:53:53Z","timestamp":1470711233000},"page":"6207-6215","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239"],"prefix":"10.1128","volume":"60","author":[{"given":"Christopher M.","family":"Owens","sequence":"first","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley B.","family":"Brasher","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Polemeropoulos","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H. J.","family":"Rhodin","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"McAllister","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Peng","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Wang","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ying","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rondon","sequence":"additional","affiliation":[{"name":"Elite Research Institute, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry D.","family":"Box","sequence":"additional","affiliation":[{"name":"University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Goethe University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[{"name":"Institute for Interdisciplinary Medicine, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lin","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ling","family":"Qiu","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colvin","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yat Sun","family":"Or","sequence":"additional","affiliation":[{"name":"ENANTA Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_3_3_3_2","first-page":"425","article-title":"Hepatitis C\u2014global prevalence (update)","volume":"74","year":"1999","unstructured":". 1999. Hepatitis C\u2014global prevalence (update). Wkly Epidemiol Rec 74:425\u2013427.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_3_4_2","volume-title":"164","year":"2016","unstructured":". 2016. Hepatitis C fact sheet no. 164. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_5_2","first-page":"991","volume-title":"Fields virology","author":"Lindenbach BD","year":"2001","unstructured":"Lindenbach BD, Rice CM. 2001. Flaviviridae: the viruses and their replication, p 991\u20131041. In Knipe DM, Howley PM (ed), Fields virology, 4th ed, vol 1. Lippincott-Raven Publishers, Philadelphia, PA.","edition":"4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20819"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80204-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508175200"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404761200"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407787200"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03580"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.02.108"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi700776e"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000009"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_3_3_17_2","first-page":"1065A","article-title":"PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety","volume":"56","author":"Lalezari J","year":"2012","unstructured":"Lalezari J, Farrell G, Shah P, Lawitz E, Schwabe C, Walsh D, Vig P, Brown N, Ruby E, Halfon S, Huang N, Huang Q, Colonno R, Li L, Johnston B, Wargin B, Gane E. 2012. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety. Hepatology 56(Suppl S1):1065A\u20131066A.","journal-title":"Hepatology"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60878-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.15.7904-7915.2004"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1437-1449.2001"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-10"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-12"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.540"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313020200"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3525-3530.2003"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02524-06"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02193-12"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00815-16"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02322290"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02524-15"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00808-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00808-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:06:58Z","timestamp":1645484818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00808-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1128\/AAC.00808-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00808-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"2016-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}